- Home
- EDIT vs RNAC Comparison
EDIT vs RNAC Comparison
Compare EDIT & RNAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDIT | RNAC |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.3M | 204.6M |
| IPO Year | 2016 | 2016 |
Fundamental Metrics
Financial Performance| Metric | EDIT | RNAC |
|---|---|---|
| Price | $2.46 | $9.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | $4.13 | ★ $38.40 |
| AVG Volume (30 Days) | ★ 1.6M | 196.3K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $46,383,000.00 | $1,091,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.91 | $5.98 |
| 52 Week High | $4.54 | $23.93 |
Technical Indicators
Market Signals| Indicator | EDIT | RNAC |
|---|---|---|
| Relative Strength Index (RSI) | 44.04 | 66.43 |
| Support Level | $2.09 | $6.66 |
| Resistance Level | $2.70 | $8.40 |
| Average True Range (ATR) | 0.17 | 0.57 |
| MACD | 0.05 | 0.27 |
| Stochastic Oscillator | 58.20 | 92.41 |
Price Performance
Historical ComparisonAbout EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
About RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.